These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38397925)

  • 61. Liver Stiffness Assessed by Ultrasound Shear Wave Elastography from General Electric Accurately Predicts Clinically Significant Portal Hypertension in Patients with Advanced Chronic Liver Disease.
    Stefanescu H; Rusu C; Lupsor-Platon M; Nicoara Farcau O; Fischer P; Grigoras C; Horhat A; Stancu O; Ardelean A; Tantau M; Badea R; Procopet B
    Ultraschall Med; 2020 Oct; 41(5):526-533. PubMed ID: 31476787
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population.
    Chon YE; Jung KS; Kim SU; Park JY; Park YN; Kim DY; Ahn SH; Chon CY; Lee HW; Park Y; Han KH
    Liver Int; 2014 Jan; 34(1):102-9. PubMed ID: 24028214
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quantification of Steatosis and Fibrosis using a new system implemented in an ultrasound machine.
    Sporea I; Bâldea V; Lupușoru R; Bende F; Mare R; Lazăr A; Popescu A; Șirli R
    Med Ultrason; 2020 Sep; 22(3):265-271. PubMed ID: 32399537
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
    Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
    Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study.
    Rivera-Esteban J; Jiménez-Masip A; Muñoz-Martínez S; Augustin S; Guerrero RA; Gabriel-Medina P; Ferrer-Costa R; Rodríguez-Frías F; Turu E; Marco A; Pericàs JM; On Behalf Of The Prisonafld Study Group Collaborators
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068330
    [TBL] [Abstract][Full Text] [Related]  

  • 66. New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode.
    Koizumi Y; Hirooka M; Tamaki N; Yada N; Nakashima O; Izumi N; Kudo M; Hiasa Y
    PLoS One; 2019; 14(8):e0221548. PubMed ID: 31454369
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study.
    Solomon A; Negrea MO; Cipăian CR; Boicean A; Mihaila R; Rezi C; Cristinescu BA; Berghea-Neamtu CS; Popa ML; Teodoru M; Stoia O; Neamtu B
    Healthcare (Basel); 2023 Oct; 11(19):. PubMed ID: 37830733
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Transient elastography and controlled attenuation parameter to evaluate hepatic steatosis and liver stiffness in postpartum patients.
    Hussain FN; Rosenbluth E; Feldman KM; Strauss TS; Schneider E; Schmidt-Beauchat E; Rodriguez-Rivas C; Brustman L; Kushner T
    J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2190838. PubMed ID: 36935368
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
    Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
    Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children.
    Chaidez A; Pan Z; Sundaram SS; Boster J; Lovell M; Sokol RJ; Mack CL
    Hepatol Commun; 2022 Nov; 6(11):3015-3023. PubMed ID: 36069338
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
    Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
    World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
    Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
    J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
    Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
    J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients.
    Liu J; Ma Y; Han P; Wang J; Liu YG; Shi RF; Li J
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101957. PubMed ID: 35609821
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
    Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
    Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Point shear wave elastography and vibration controlled transient elastography for estimating liver fibrosis in a cohort of liver transplant patients.
    Valente G; Rinaldi L; Moggio G; Piai G
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7357-7365. PubMed ID: 32706074
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes.
    Mertens J; Weyler J; Dirinck E; Vonghia L; Kwanten WJ; Mortelmans L; Peleman C; Chotkoe S; Spinhoven M; Vanhevel F; Van Gaal LF; De Winter BY; De Block CEM; Francque SM
    JHEP Rep; 2023 Jul; 5(7):100753. PubMed ID: 37274774
    [TBL] [Abstract][Full Text] [Related]  

  • 79. FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease.
    Arvaniti P; Giannoulis G; Lygoura V; Gatselis NK; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K; Dalekos GN
    Ann Gastroenterol; 2023; 36(6):661-669. PubMed ID: 38023979
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population.
    Ciardullo S; Monti T; Grassi G; Mancia G; Perseghin G
    J Hypertens; 2021 Aug; 39(8):1621-1627. PubMed ID: 33657584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.